A Big Week for Psychedelic Stocks: 2 CEOs Step Down, MDMA Patents and a Phase 3 Trial
Compass Pathways and Small Pharma announce executive shakeup, Mydecine and Awakn push forward with new research
Awakn Life Sciences
Elon Musk Excites Psychedelic Industry CEOs with This Tweet
This is one of the billionaire’s most explicit acknowledgments of the power of psychedelics for mental health applications.
5 Most Important Psychedelic Clinical Trials in 2022
Here’s why we think MAPS’ second Phase 3 MDMA trial is the most important psychedelic study of 2022, and 4 more that may have huge impacts.
Ketamine Trial for Alcohol Use Disorder Delivers Very Promising Results
Awakn Life Sciences’ Head of Ketamine-Assisted Therapy, Professor Celia Morgan, says world’s first controlled trial to investigate efficacy of ketamine-assisted therapy for treatment of Alcohol Use Disorder “paves the way for a paradigm shift.”
Psychedelic Business Spotlight — January 7
This week in psychedelic business news: Mindset Pharma partners with global pharmaceutical company; Awakn Life Sciences explores behavioral addictions; Ei.Ventures buys virtual land for psychedelic therapy.
Psychedelic Business Spotlight: November 19
This week in psychedelic business news: Companies partner on new dosage method; MindMed investigates LSD microdosing; Health Canada allows a psilocybin production campus.
Psychedelic Business Spotlight: October 29
This week in psychedelic business news: MindMed’s MDMA research pipeline to treat Autism Spectrum Disorder; Cybin EMBARKs; Awakn and MindCure partner to heal alcoholism.
Psychedelic Business Spotlight: September 17, 2021
This week in psychedelic business news: Wesana teams up with MAPS, MindBio Therapeutics announces world-class research and drug development facility, and Awakn Life Sciences buys up ketamine clinics across the Nordics.
Awakn Life Sciences CEO Details ‘Groundbreaking’ MDMA Discovery in Quest to Treat Addiction
Anthony Tennyson tells the Psychedelic Spotlight Podcast that his company has “discovered receptor sites that MDMA interacts with that we believe nobody else in the world knows about.”
U.K. Psychedelic R&D Company Investigates MDMA, Ketamine for Addiction
Awakn Life Sciences is looking at psychedelics for addiction, namely MDMA and ketamine for alcohol use disorder.
End of content
End of content